Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To evaluate the effect of caplacizumab on prevention of recurrence of aTTP (proportion of participants with a recurrence of aTTP) during the overall study period.
Secondary Objectives:
To evaluate effect of caplacizumab on
To evaluate safety profile of caplacizumab in Japanese patients
To evaluate effect of caplacizumab on pharmacodynamic (PD) markers in Japanese patients
To evaluate pharmacokinetic (PK) profile of caplacizumab in Japanese patients
To evaluate immunogenicity of caplacizumab in Japanese patients
Full description
Study duration per participant is approximately 2 months up to approximately 6 months in case of treatment extension and recurrence during the study drug treatment period.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion criteria :
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
21 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal